RTOG 0619: A Randomized Phase II Trial of Chemoradiotherapy versus Chemoradiotherapy and Vandetanib for High Risk Postoperative Advanced Squamous Cell Carcinoma of the Head and Neck.
Phase of Trial: Phase II
Latest Information Update: 12 Jul 2013
At a glance
- Drugs Vandetanib (Primary) ; Cisplatin
- Indications Head and neck cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 09 Aug 2011 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 09 Aug 2011 Actual end date (Aug 2011) added as reported by ClinicalTrials.gov.